Pennystocksupdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 09/04/2013 -- Shares of Astex Pharmaceuticals, Inc.(NASDAQ:ASTX), which has a market capitalization of $634.2 million as of Wednesday, rose as much as 41 percent to a nine-year high of $9.39 on the Nasdaq. Astex, whose only approved drug, Dacogen, treats a blood disorder called myelodysplastic syndromes, is developing drugs to treat prostate, lung and ovarian cancer.
The company has a total of 94.94million outstanding shares and its total market capitalization is $621.88 million. Its beta value stands at1.14 times and earnings per share were $-0.01.
Astex Pharmaceuticals, Inc. engages in the discovery and development of small molecule therapeutics with a focus on oncology and hematology using its fragment-based drug discovery platform, Pyramid.
How Should Investors Trade ASTX Now? Find Out Here
Gilead Sciences, Inc. (NASDAQ:GILD) soared 0.31% to $61.11. Gilead Sciences has a one year low of $28.85 and a one year high of $64.04. The stock has a 50-day moving average of $59.68 and a 200-day moving average of $52.65. The company has a market cap of $93.246 billion and a P/E ratio of 34.09. The company reported $0.50 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.50. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.66 billion.
During the same quarter last year, the company posted $0.99 earnings per share. Gilead Sciences’s revenue was up 14.5% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $1.97 earnings per share for the current fiscal year.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
How Should Investors Trade GILD After The Recent Volatile Moves? Find Out Here
Cerus Corporation (NASDAQ:CERS) showed noticeable changes in its stock market in the beginning of August. On August 7, it decreased -1.01% and closed at $5.86 on a trade volume of one million shares, in comparison to 5, 46,994 shares that is of average volume.
The stock is so far up over 82.55%. The Cerus Corporation has the total market capitalization of $408.54 million and the total outstanding shares are 69.72 million. Cantor Fitzgerald currently has a buy rating on the stock. The latest change stands at +0.39/ 7.46%. The net volume running is 912.7 million.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety.
Can CERS Extend Rally? Find Out Here
Shares of Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) touched a new 52-week high of $5.50 on Tuesday before closing at $5.39, following the settlement of a pending patent litigation with Actavis related to Nuedexta, a drug approved to help manage uncontrollable emotional outbursts.
Avanir had sued Par, Actavis, Wockhardt, Impax and Watson to prevent them from marketing a generic version of NUEDEXTA. The 5 generic drug companies have submitted ANDA filings for Avanir's NUEDEXTA.
Avanir entered into a settlement agreement with Sandoz related to the NUEDEXTA patent suit last month.
Can AVNR Extend Gain? If Yes, How Far It Can Go? Find Out Here
Neither Pennystocksupdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Pennystocksupdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. Pennystocksupdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Pennystocksupdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)